Suppr超能文献

印度轮状病毒疫苗接种的证据基础:现状与未来需求

The evidence base for rotavirus vaccination in India: Current status, future needs.

作者信息

Bhat Niranjan, Vodicka Elisabeth, Clifford Allison, Ananth Kanduri Balaji, Bavdekar Ashish, Roy Arup Deb, Parashar Umesh, Tate Jacqueline, Haldar Pradeep, Kang Gagandeep

机构信息

Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.

Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.

出版信息

Vaccine. 2025 Jan 12;44:126551. doi: 10.1016/j.vaccine.2024.126551. Epub 2024 Nov 29.

Abstract

Rotavirus is a leading cause of severe diarrheal disease in infants and young children worldwide. Vaccination offers the best protection against this disease, and two rotavirus vaccines were developed in India and included in its routine immunization program. The Government of India's decision to adopt this intervention was supported by a solid base of evidence from clinical trials, as well as substantial research regarding rotavirus disease burden and the potential health and economic value of immunization. Following program implementation, multiple studies were initiated, including three evaluations of effectiveness and several investigations regarding intussusception. These additional data regarding vaccine impact, safety, and delivery from post-introduction evaluations in conditions of real-world use will further strengthen and sustain the immunization program. This manuscript evaluates the status of existing and forthcoming evidence regarding rotavirus vaccination in India through a literature review and consultation with relevant stakeholders. Studies evaluating vaccine impact, effectiveness, safety, health economics, and acceptability, as well as operational and programmatic research, were included in the review. Overall, we found that the evidence base did not contain any major gaps. Nevertheless, additional smaller-scale research studies would be valuable in providing a more complete picture of rotavirus vaccine performance and benefit. Documentation of India's experience with rotavirus vaccines may provide lessons learned for other countries in the Asia region, where rotavirus disease burden remains high, yet vaccine adoption has been slow, as well as for countries worldwide that may be considering implementation of the Indian-made rotavirus vaccines.

摘要

轮状病毒是全球婴幼儿严重腹泻疾病的主要病因。接种疫苗是预防该疾病的最佳手段,印度研发了两种轮状病毒疫苗并将其纳入国家常规免疫规划。印度政府采用这一干预措施的决定得到了临床试验确凿证据的支持,以及关于轮状病毒疾病负担和免疫接种潜在健康及经济价值的大量研究的支持。在项目实施后,开展了多项研究,包括三项有效性评估以及几项关于肠套叠的调查。这些在实际使用条件下引入疫苗后的评估中获得的关于疫苗影响、安全性和接种情况的额外数据,将进一步加强和维持免疫规划。本手稿通过文献综述和与相关利益攸关方的磋商,评估了印度轮状病毒疫苗现有和即将出现的证据的状况。评估疫苗影响、有效性、安全性、卫生经济学和可接受性的研究,以及运营和规划研究均纳入了综述。总体而言,我们发现证据基础不存在任何重大空白。然而,更多小规模研究对于更全面地了解轮状病毒疫苗的性能和益处将是有价值的。记录印度使用轮状病毒疫苗的经验,可能为亚洲区域其他国家提供经验教训,这些国家的轮状病毒疾病负担仍然很高,但疫苗采用速度缓慢,也可为全球其他可能考虑采用印度生产的轮状病毒疫苗的国家提供经验教训。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1fb/11672240/c2a927584846/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验